Does Keynote 189 establish combination chemoimmunotherapy as the standard of care for Stage IV lung adenocarcinoma?

If the Insigna trial is available, to me that is the best way of addressing this. Otherwise I would not. To me KN189/407 represents the current standard of care in the US relative to KN42 which appears inferior. For those that make argument about patient with poor performance status etc for KN42, th...